Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress

Vashma Junaid; Abdul Mannan Khan Minhas; Maha Inam; Colin Hinkamp; Khawaja M. Talha; Chelsea Meloche; Sana Sheikh; Adeel Khoja; Chayakrit Krittanawong; Elizabeth M. Vaughan; Dinesh K. Kalra; Leandro Slipczuk; Salim S. Virani

doi:10.1007/s11883-024-01253-z

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress

Vashma Junaid, Abdul Mannan Khan Minhas, Maha Inam, Colin Hinkamp, Khawaja M. Talha, Chelsea Meloche, Sana Sheikh, Adeel Khoja, Chayakrit Krittanawong, Elizabeth M. Vaughan, Dinesh K. Kalra, Leandro Slipczuk, Salim S. Virani

Research output: Contribution to journal › Review article › peer-review

Abstract

Purpose of Review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress. Recent Findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. Summary: The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.

Original language	English
Article number	14
Journal	Current Atherosclerosis Reports
Volume	27
Issue number	1
DOIs	https://doi.org/10.1007/s11883-024-01253-z
Publication status	Published - Dec 2024

Keywords

Apolipoprotein A-1
CACS
CVD Prevention
ESC
LDL-c
Lp(a)
MACE
Plozasiran

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s11883-024-01253-z

Cite this

Junaid, V., Minhas, A. M. K., Inam, M., Hinkamp, C., Talha, K. M., Meloche, C., Sheikh, S., Khoja, A., Krittanawong, C., Vaughan, E. M., Kalra, D. K., Slipczuk, L., & Virani, S. S. (2024). Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress. Current Atherosclerosis Reports, 27(1), Article 14. https://doi.org/10.1007/s11883-024-01253-z

@article{f362e0925cbf4f869607e86b3f6334ed,

title = "Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress",

abstract = "Purpose of Review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress. Recent Findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. Summary: The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.",

keywords = "Apolipoprotein A-1, CACS, CVD Prevention, ESC, LDL-c, Lp(a), MACE, Plozasiran",

author = "Vashma Junaid and Minhas, {Abdul Mannan Khan} and Maha Inam and Colin Hinkamp and Talha, {Khawaja M.} and Chelsea Meloche and Sana Sheikh and Adeel Khoja and Chayakrit Krittanawong and Vaughan, {Elizabeth M.} and Kalra, {Dinesh K.} and Leandro Slipczuk and Virani, {Salim S.}",

note = "Publisher Copyright: {\textcopyright} The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.",

year = "2024",

month = dec,

doi = "10.1007/s11883-024-01253-z",

language = "English",

volume = "27",

journal = "Current Atherosclerosis Reports",

issn = "1523-3804",

publisher = "Current Medicine Group",

number = "1",

}

Junaid, V, Minhas, AMK, Inam, M, Hinkamp, C, Talha, KM, Meloche, C, Sheikh, S, Khoja, A, Krittanawong, C, Vaughan, EM, Kalra, DK, Slipczuk, L & Virani, SS 2024, 'Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress', Current Atherosclerosis Reports, vol. 27, no. 1, 14. https://doi.org/10.1007/s11883-024-01253-z

TY - JOUR

T1 - Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 European Society of Cardiology Congress

AU - Junaid, Vashma

AU - Minhas, Abdul Mannan Khan

AU - Inam, Maha

AU - Hinkamp, Colin

AU - Talha, Khawaja M.

AU - Meloche, Chelsea

AU - Sheikh, Sana

AU - Khoja, Adeel

AU - Krittanawong, Chayakrit

AU - Vaughan, Elizabeth M.

AU - Kalra, Dinesh K.

AU - Slipczuk, Leandro

AU - Virani, Salim S.

N1 - Publisher Copyright: © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024.

PY - 2024/12

Y1 - 2024/12

N2 - Purpose of Review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress. Recent Findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. Summary: The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.

AB - Purpose of Review: To summarize selected late-breaking science on cardiovascular disease (CVD) prevention presented at the 2024 European Society of Cardiology (ESC) Congress. Recent Findings: Key studies from the 2024 ESC Congress highlight advances in (CVD) management. Apolipoprotein A-1 infusions reduced risk in acute myocardial infarction patients with high LDL cholesterol. Plozasiran cut triglycerides and apolipoprotein C-III levels, lowering pancreatitis risk. A 14-year study linked smoking among youth to cardiac abnormalities. Baseline hsCRP, LDL-C, and Lp(a) were strong predictors of 30-year outcomes in women. Alternative LDL-lowering strategies matched high-intensity statins in effectiveness of LDL-C lowering and reduced diabetes risk. Early combination lipid lowering therapy improved outcomes post-myocardial infarction. Nordic and Mediterranean diets were linked to lower atherosclerotic CVD risk. Summary: The findings from the 2024 ESC Congress highlight significant advancements in CVD prevention, including novel lipid-lowering therapies, biomarker-based risk prediction, and lifestyle interventions. These studies underscore the importance of early and personalized treatment strategies to mitigate long-term cardiovascular risk.

KW - Apolipoprotein A-1

KW - CACS

KW - CVD Prevention

KW - ESC

KW - LDL-c

KW - Lp(a)

KW - MACE

KW - Plozasiran

UR - http://www.scopus.com/inward/record.url?scp=85211221972&partnerID=8YFLogxK

U2 - 10.1007/s11883-024-01253-z

DO - 10.1007/s11883-024-01253-z

M3 - Review article

C2 - 39621242

AN - SCOPUS:85211221972

SN - 1523-3804

VL - 27

JO - Current Atherosclerosis Reports

JF - Current Atherosclerosis Reports

IS - 1

M1 - 14

ER -